Is Very High Sympathetic Tone in Heart Failure a Result of Keeping Bad Company?

Hypertension

Volumn 42, Issue 5, 2003, Pages 870-872

  Esler, Murray ^a   Kaye, David ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC SYSTEM; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DEATH; DISEASE ASSOCIATION; EDITORIAL; HEART FAILURE; HYPERTENSION; OBESITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SYMPATHETIC NERVE; SYMPATHETIC TONE;

HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 0242525143     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000098662.31444.13     Document Type: Editorial

References (23)

1. Hasking G, Esler M, Jennings G, Burton D, Johns J, Korner P. Norepinephrine spillover to plasma in congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
2. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension. 1998;31:64-67.
3. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate and functions. Physiol Rev. 1990;70:963-985.
4. Cohn JN, Levine TB, Olivari MT, Garberg V, Tura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
5. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
6. Packer M, Bristow MR, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
7. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II). Lancet. 1999;353:9-13.
8. Patel KP, Zhang K. Neurohumoral activation in heart failure: role of paraventricular nucleus. Clin Exp Pharmacol Physiol. 1996;23:722-726.
9. Lambert GW, Kaye DM, Lefkovits J, Jennings GL, Turner AG, Cox HS, Esler MD. Central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Circulation. 1995;92:1813-1818.
10. Aggarwal A, Esler M, Lambert G, Hastings J, Johnston L, Kaye D. Norepinephrine turnover is increased in suprabulbar subcortical brain regions and is related to whole-body sympathetic activity in human heart failure. Circulation. 2002;105:1031-1033.
11. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M, Mancia G. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206-3211.
12. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, Wiesner GH, Brunner-La Rocca HP, Esler MD. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125-1133.
13. Ferrier C, Esler M, Eisenhofer G, Wallin G, Horne M, Cox H, Lambert G, Jennings G. Increased norepinephrine spillover into the cerebrovascular circulation in essential hypertension: evidence of high central nervous system norepinephrine turnover? Hypertension. 1992;19:62-69.
14. Qualy JM, Westfall TC. Age-dependent overflow of endogenous norepinephrine from paraventricular hypothalamic nucleus of hypertensive rats. Am J Physiol. 1993;265:H39-H46.
15. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension. 1997;30:619-623.
16. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986;236:1081-1090.
17. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation. 1998;98:772-776.
18. Korner PI. Integrative neural cardiovascular control. Physiol Rev. 1971; 51:312-367.
19. Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med. 1964;271:403-409.
20. Di Bona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am J Physiol. 1988;254:R1017-R1024.
21. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003;13:379-382.
22. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Soctratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-565.
23. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.